Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 11/20 | 0.57 |
| ▸ | RARA | P10276 | 4/20 | 0.51 |
| ▸ | RARB | P10826 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 4/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.37 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032936 | 0.93 | RARG (0.57) | RARGRARARARBRXRAIKBKB | |
| SCHEMBL6032671 | 0.87 | RARG (0.51) | RARGRARARARBRXRAIKBKB | |
| SCHEMBL6033298 | 0.85 | RARG (0.41) | RARGRARARARBRXRACYP26A1 | |
| SCHEMBL6033032 | 0.85 | RARG (0.56) | RARGRARARARBRXRAIKBKB | |
| SCHEMBL6032919 | 0.84 | MRGPRX4 (0.48) | RXRA | |
| SCHEMBL6032623 | 0.79 | RARG (0.61) | RARGRARARARBRXRAIKBKB | |
| SCHEMBL6032816 | 0.79 | RARG (0.54) | RARGRARARARBRXRAIKBKB | |
| SCHEMBL6033300 | 0.78 | RXRA (0.39) | RARGRARARARBRXRAHNF4A | |
| SCHEMBL6032934 | 0.78 | RARG (0.41) | RARGRARARARBRXRACYP26A1 | |
| SCHEMBL6033014 | 0.76 | RARG (0.45) | RARGRARARARBRXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | claimed |
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RARG 2050/4885RARA 2083/4885RARB 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.